Evidence map›Paper›PMID 20086172›Full record

ArticleCancer research2010

The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.

Eric A Ariazi, Eugen Brailoiu, Smitha Yerrum, Heather A Shupp, Michael J Slifker, Heather E Cunliffe, Michael A Black, Anne L Donato, Jeffrey B Arterburn, Tudor I Oprea and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 235 citations in OpenAlex.

  1. Oxidative Stress as a Physiological Pain Response in Full-Term Newborns.Oxidative medicine and cellular longevity · 2017
    Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Mitochondrial CaJournal of cellular physiology · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers.International journal of molecular sciences · 2022
    Review
  20. Article

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Eric A AriaziFox Chase Cancer Center; Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania, USA.
Eugen Brailoiu
Smitha Yerrum
Heather A Shupp
Michael J Slifker
Heather E Cunliffe
Michael A Black
Anne L Donato
Jeffrey B Arterburn
Tudor I Oprea
Eric R Prossnitz
Nae J Dun
V Craig Jordan
Temple University · USUniversity of New Mexico · USUniversity of Otago · NZNew Mexico State University · USTranslational Genomics Research Institute · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
Yeast Biology ConsortiumU54MH084690 · NIMH · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI TEGOS, GEORGE P · 2008 to 2013
$14.4M
ACTIVITY OF BRAINSTEM NEURONSR01HL051314 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI DUN, NAE J · 1995 to 2010
$2.3M
Activity of Preganglionic Neurons in VitroR37NS018710 · NINDS · TEMPLE UNIV OF THE COMMONWEALTH · PI DUN, NAE J · 2003 to 2009
$2.2M
Development of GPR30-Selective LigandsR01CA127731 · NCI · UNIVERSITY OF NEW MEXICO · PI ARTERBURN, JEFFREY B, OPREA, TUDOR I · 2008 to 2012
$1.7M
Role of nonnuclear estrogen receptor GPR30 in preganglionic vagal neuronsR01HL090804 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI BRAILOIU, EUGEN · 2009 to 2012
$1.5M
A novel intracellular 7TM estrogen receptor in breastR01CA116662 · NCI · UNIVERSITY OF NEW MEXICO · PI PROSSNITZ, ERIC R · 2006 to 2010
$1.3M
ACTIVITY O PREGANGLIONIC NEURONS IN VITROR01NS018710 · NINDS · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI DUN, NAE J · 1985 to 2001
$493k
NCI NIH HHS CA116662NCI NIH HHS CA118100NCI NIH HHS CA127731NCI NIH HHS P30 CA006927NCI NIH HHS P30CA006927NCI NIH HHS P30 CA118100NCI NIH HHS R01 CA116662NCI NIH HHS R01 CA127731NHLBI NIH HHS HL090804NHLBI NIH HHS HL090804-01A2S109NHLBI NIH HHS HL51314NHLBI NIH HHS R01 HL051314NHLBI NIH HHS R01 HL090804NIMH NIH HHS U54 MH084690NIMH NIH HHS U54MH084690NINDS NIH HHS NS18710NINDS NIH HHS R01 NS018710NINDS NIH HHS R37 NS018710
6 · The paper itself

Abstract

The G protein-coupled receptor GPR30 binds 17beta-estradiol (E(2)) yet differs from classic estrogen receptors (ERalpha and ERbeta). GPR30 can mediate E(2)-induced nongenomic signaling, but its role in ERalpha-positive breast cancer remains unclear. Gene expression microarray data from five cohorts comprising 1,250 breast carcinomas showed an association between increased GPR30 expression and ERalpha-positive status. We therefore examined GPR30 in estrogenic activities in ER-positive MCF-7 breast cancer cells using G-1 and diethylstilbestrol (DES), ligands that selectively activate GPR30 and ER, respectively, and small interfering RNAs. In expression studies, E(2) and DES, but not G-1, transiently downregulated both ER and GPR30, indicating that this was ER mediated. In Ca(2+) mobilization studies, GPR30, but not ERalpha, mediated E(2)-induced Ca(2+) responses because E(2), 4-hydroxytamoxifen (activates GPR30), and G-1, but not DES, elicited cytosolic Ca(2+) increases not only in MCF-7 cells but also in ER-negative SKBr3 cells. Additionally, in MCF-7 cells, GPR30 depletion blocked E(2)-induced and G-1-induced Ca(2+) mobilization, but ERalpha depletion did not. Interestingly, GPR30-coupled Ca(2+) responses were sustained and inositol triphosphate receptor mediated in ER-positive MCF-7 cells but transitory and ryanodine receptor mediated in ER-negative SKBr3 cells. Proliferation studies involving GPR30 depletion indicated that the role of GPR30 was to promote SKBr3 cell growth but reduce MCF-7 cell growth. Supporting this, G-1 profoundly inhibited MCF-7 cell growth, potentially via p53 and p21 induction. Further, flow cytometry showed that G-1 blocked MCF-7 cell cycle progression at the G(1) phase. Thus, GPR30 antagonizes growth of ERalpha-positive breast cancer and may represent a new target to combat this disease.

Indexed as

Cell ProliferationBreast NeoplasmsCalciumCell Line, TumorCyclin-Dependent Kinase Inhibitor p21CyclopentanesDiethylstilbestrolEstradiolEstrogen Receptor alphaEstrogensFemaleFlow CytometryG1 PhaseGene Expression Regulation, NeoplasticHumansImmunoblotting1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanoneCalciumCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21CyclopentanesDiethylstilbestrolEstradiolEstrogen Receptor alphaEstrogensGPER1 protein, humanQuinolinesReceptors, EstrogenReceptors, G-Protein-CoupledTumor Suppressor Protein p53

Identifiers

PMID20086172
PMCPMC2879282
OpenAlexW2148764267

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.